Clinical Trial Update: Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors [Phase 1]

View source ↗

Summary

Phase 1 results for a Granzyme B PET imaging agent studied as a predictor of response to checkpoint inhibitor immunotherapy in adults with solid tumors and lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• Granzyme B PET imaging agent

Snippet

Sponsor: Cytosite Biopharma Inc. | Conditions: Solid Tumor, Unspecified, Adult, Lymphoma | Phase 1 | Status: COMPLETED